Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,29620701,tmax,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,6.0,3336,DB01452,Heroin
,29620701,tmax,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,6.3,3337,DB01452,Heroin
,29620701,t1/2,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,11,3338,DB01452,Heroin
,29620701,t1/2,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,12,3339,DB01452,Heroin
,29620701,CSSmax,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],100,3340,DB01452,Heroin
,29620701,CSSmax,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],58.4,3341,DB01452,Heroin
,29620701,CSSmin,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],39.5,3342,DB01452,Heroin
,29620701,CSSmin,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],21.8,3343,DB01452,Heroin
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,30,3433,DB01452,Heroin
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,54,3434,DB01452,Heroin
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,67,3435,DB01452,Heroin
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,82,3436,DB01452,Heroin
,23165127,hair elimination half-lives,"Assuming a rate of hair growth of 1cm/month, the mean hair elimination half-lives of 6-AM, MOR and COD were 0.88 months (95% CI, 0.74-1.03), 0.73 months (95% CI, 0.64-0.81), and 0.61 months (95% CI, 0.54-0.69), respectively.","Disappearance of 6-acetylmorphine, morphine and codeine from human scalp hair after discontinuation of opiate abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23165127/),month,0.88,10593,DB01452,Heroin
,23165127,hair elimination half-lives,"Assuming a rate of hair growth of 1cm/month, the mean hair elimination half-lives of 6-AM, MOR and COD were 0.88 months (95% CI, 0.74-1.03), 0.73 months (95% CI, 0.64-0.81), and 0.61 months (95% CI, 0.54-0.69), respectively.","Disappearance of 6-acetylmorphine, morphine and codeine from human scalp hair after discontinuation of opiate abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23165127/),month,0.73,10594,DB01452,Heroin
,23165127,hair elimination half-lives,"Assuming a rate of hair growth of 1cm/month, the mean hair elimination half-lives of 6-AM, MOR and COD were 0.88 months (95% CI, 0.74-1.03), 0.73 months (95% CI, 0.64-0.81), and 0.61 months (95% CI, 0.54-0.69), respectively.","Disappearance of 6-acetylmorphine, morphine and codeine from human scalp hair after discontinuation of opiate abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23165127/),month,0.61,10595,DB01452,Heroin
,6709027,half-life,"The mean half-life of heroin (+/- S.D.) after intravenous injection or infusion was only 3.0 +/- 1.3 minutes, and the mean clearance of heroin from the blood at apparent steady state was 30.8 +/- 2.1 ml per kilogram of body weight per minute.",The pharmacokinetics of heroin in patients with chronic pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6709027/),min,3.0,10667,DB01452,Heroin
,6709027,clearance of heroin from the blood at apparent steady state,"The mean half-life of heroin (+/- S.D.) after intravenous injection or infusion was only 3.0 +/- 1.3 minutes, and the mean clearance of heroin from the blood at apparent steady state was 30.8 +/- 2.1 ml per kilogram of body weight per minute.",The pharmacokinetics of heroin in patients with chronic pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6709027/),[ml] / [kg],30.8,10668,DB01452,Heroin
,9248943,flow rate,The chromatographic separation of the analytes was achieved using a normal phase column and a water-methanol-acetonitrile-formic acid mobile phase at a flow rate of 230 microL/min.,"Simultaneous determination of heroin 6-monoacetylmorphine, morphine, and its glucuronides by liquid chromatography--atmospheric pressure ionspray-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248943/),[μl] / [min],230,13068,DB01452,Heroin
,9248943,peak concentration,"6-monoacetylmorphine showed a peak concentration of 0.93 micrograms/mL serum at 3 min, whereas morphine and morphine-3-glucuronide achieved their peak concentrations of 9.6 and 2.9 micrograms/mL serum at 10 and 20 min, respectively.","Simultaneous determination of heroin 6-monoacetylmorphine, morphine, and its glucuronides by liquid chromatography--atmospheric pressure ionspray-mass spectrometry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248943/),[μg] / [ml·serum],0.93,13069,DB01452,Heroin
,9248943,peak concentrations,"6-monoacetylmorphine showed a peak concentration of 0.93 micrograms/mL serum at 3 min, whereas morphine and morphine-3-glucuronide achieved their peak concentrations of 9.6 and 2.9 micrograms/mL serum at 10 and 20 min, respectively.","Simultaneous determination of heroin 6-monoacetylmorphine, morphine, and its glucuronides by liquid chromatography--atmospheric pressure ionspray-mass spectrometry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248943/),[μg] / [ml·serum],9.6,13070,DB01452,Heroin
,9248943,peak concentrations,"6-monoacetylmorphine showed a peak concentration of 0.93 micrograms/mL serum at 3 min, whereas morphine and morphine-3-glucuronide achieved their peak concentrations of 9.6 and 2.9 micrograms/mL serum at 10 and 20 min, respectively.","Simultaneous determination of heroin 6-monoacetylmorphine, morphine, and its glucuronides by liquid chromatography--atmospheric pressure ionspray-mass spectrometry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248943/),[μg] / [ml·serum],2.9,13071,DB01452,Heroin
,18945270,bioavailability,"However, morphine bioavailability was considerably higher in chronic users [diacetylmorphine 45.6% (95% confidence interval 40.0, 51.3), morphine 37.2% (30.1, 44.3)] than in naive subjects [diacetylmorphine 22.9% (16.4, 29.4), morphine 23.9% (16.5, 31.2)] after low oral doses (48.5 micromol) of either diacetylmorphine or morphine.",Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18945270/),%,45.6,13185,DB01452,Heroin
,18945270,bioavailability,"However, morphine bioavailability was considerably higher in chronic users [diacetylmorphine 45.6% (95% confidence interval 40.0, 51.3), morphine 37.2% (30.1, 44.3)] than in naive subjects [diacetylmorphine 22.9% (16.4, 29.4), morphine 23.9% (16.5, 31.2)] after low oral doses (48.5 micromol) of either diacetylmorphine or morphine.",Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18945270/),%,37.2,13186,DB01452,Heroin
,18945270,bioavailability,"However, morphine bioavailability was considerably higher in chronic users [diacetylmorphine 45.6% (95% confidence interval 40.0, 51.3), morphine 37.2% (30.1, 44.3)] than in naive subjects [diacetylmorphine 22.9% (16.4, 29.4), morphine 23.9% (16.5, 31.2)] after low oral doses (48.5 micromol) of either diacetylmorphine or morphine.",Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18945270/),%,22.9,13187,DB01452,Heroin
,18945270,bioavailability,"However, morphine bioavailability was considerably higher in chronic users [diacetylmorphine 45.6% (95% confidence interval 40.0, 51.3), morphine 37.2% (30.1, 44.3)] than in naive subjects [diacetylmorphine 22.9% (16.4, 29.4), morphine 23.9% (16.5, 31.2)] after low oral doses (48.5 micromol) of either diacetylmorphine or morphine.",Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18945270/),%,23.9,13188,DB01452,Heroin
,18945270,bioavailability,"Moreover, oral absorption of morphine from diacetylmorphine was found to be dose dependent, with bioavailability reaching 64.2% (55.3, 73.1) for high diacetylmorphine doses (1601 micromol).",Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18945270/),%,64.2,13189,DB01452,Heroin
,22595262,flow rate,"The separation was performed on LichroCART RP-18e with particle size of 5 µm (250 × 4.6 mm) with mobile phase acetonitrile-50 mM KH(2)PO(4) buffer, pH 7.1, using a gradient mode with a 1.0 mL/min flow rate.",New HPLC method to detect individual opioids (heroin and tramadol) and their metabolites in the blood of rats on combination treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595262/),[ml] / [min],1.0,24703,DB01452,Heroin
,22595262,Recovery,Recovery values for the substances ranged between 59 and 83%.,New HPLC method to detect individual opioids (heroin and tramadol) and their metabolites in the blood of rats on combination treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595262/),%,59 and 83,24704,DB01452,Heroin
,25687617,peak serum concentration,Ibogaine was confirmed in his urine and serum with a peak serum concentration of 377 ng/mL.,"Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687617/),[ng] / [ml],377,28805,DB01452,Heroin
,32650192,time for,"The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively.",Protracted renal clearance of fentanyl in persons with opioid use disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32650192/),d,7.3,35406,DB01452,Heroin
,32650192,time for,"The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively.",Protracted renal clearance of fentanyl in persons with opioid use disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32650192/),d,13.3,35407,DB01452,Heroin
,32650192,clearance,"The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively.",Protracted renal clearance of fentanyl in persons with opioid use disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32650192/),d,7.3,35408,DB01452,Heroin
,32650192,clearance,"The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively.",Protracted renal clearance of fentanyl in persons with opioid use disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32650192/),d,13.3,35409,DB01452,Heroin
,499301,t1/2,The t1/2 of oral methadone-d3 was shorter (22 +/- 2 h) than that of methadone-d0 (52 +/- 20 h).,Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499301/),h,22,39352,DB01452,Heroin
,499301,t1/2,The t1/2 of oral methadone-d3 was shorter (22 +/- 2 h) than that of methadone-d0 (52 +/- 20 h).,Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499301/),h,52,39353,DB01452,Heroin
,19793724,Peak plasma morphine concentrations,"Peak plasma morphine concentrations were higher (median 109 vs 36 nmol/l), and occurred earlier (median 2 vs 10 min), with greater area under the curve (3761 vs 1794 nmol/l/h) following intravenous compared to intranasal diamorphine (all p<0.001, Mann-Whitney U test).",Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19793724/),[nM] / [l],109,40849,DB01452,Heroin
,19793724,Peak plasma morphine concentrations,"Peak plasma morphine concentrations were higher (median 109 vs 36 nmol/l), and occurred earlier (median 2 vs 10 min), with greater area under the curve (3761 vs 1794 nmol/l/h) following intravenous compared to intranasal diamorphine (all p<0.001, Mann-Whitney U test).",Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19793724/),[nM] / [l],36,40850,DB01452,Heroin
,19793724,area under the curve,"Peak plasma morphine concentrations were higher (median 109 vs 36 nmol/l), and occurred earlier (median 2 vs 10 min), with greater area under the curve (3761 vs 1794 nmol/l/h) following intravenous compared to intranasal diamorphine (all p<0.001, Mann-Whitney U test).",Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19793724/),[nM] / [h·l],3761,40851,DB01452,Heroin
,19793724,area under the curve,"Peak plasma morphine concentrations were higher (median 109 vs 36 nmol/l), and occurred earlier (median 2 vs 10 min), with greater area under the curve (3761 vs 1794 nmol/l/h) following intravenous compared to intranasal diamorphine (all p<0.001, Mann-Whitney U test).",Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19793724/),[nM] / [h·l],1794,40852,DB01452,Heroin
,19793724,plasma concentrations,"Higher plasma concentrations at 60 min (47 vs 32 nmol/l) were also observed following intravenous diamorphine (p = 0.01, Mann-Whitney U test).",Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19793724/),[nM] / [l],47,40853,DB01452,Heroin
,19793724,plasma concentrations,"Higher plasma concentrations at 60 min (47 vs 32 nmol/l) were also observed following intravenous diamorphine (p = 0.01, Mann-Whitney U test).",Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19793724/),[nM] / [l],32,40854,DB01452,Heroin
,15667599,volume of distribution for the central compartment,The volume of distribution for the central compartment was estimated to be 45.7 l and the apparent elimination rate constant of caffeine at 8 hr after inhalation was 0.150 hr(-1) for a typical individual.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),l,45.7,41945,DB01452,Heroin
,15667599,apparent elimination rate constant,The volume of distribution for the central compartment was estimated to be 45.7 l and the apparent elimination rate constant of caffeine at 8 hr after inhalation was 0.150 hr(-1) for a typical individual.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),1/[hr],0.150,41946,DB01452,Heroin
,15667599,bioavailability,The bioavailability was approximately 60%.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),%,60,41947,DB01452,Heroin
,15667599,bioavailability,The bioavailability of inhaled caffeine is approximately 60% in experienced smokers.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),%,60,41948,DB01452,Heroin
,7823539,elimination half-lives,"Mean elimination half-lives for heroin, 6-acetylmorphine, and morphine were 3.3 min, 5.4 min, and 18.8 min, respectively, by the smoked route.",Pharmacokinetics and pharmacodynamics of smoked heroin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7823539/),min,3.3,46890,DB01452,Heroin
,7823539,elimination half-lives,"Mean elimination half-lives for heroin, 6-acetylmorphine, and morphine were 3.3 min, 5.4 min, and 18.8 min, respectively, by the smoked route.",Pharmacokinetics and pharmacodynamics of smoked heroin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7823539/),min,5.4,46891,DB01452,Heroin
,7823539,elimination half-lives,"Mean elimination half-lives for heroin, 6-acetylmorphine, and morphine were 3.3 min, 5.4 min, and 18.8 min, respectively, by the smoked route.",Pharmacokinetics and pharmacodynamics of smoked heroin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7823539/),min,18.8,46892,DB01452,Heroin
,1811505,half-life,"The short half-life of codeine in serum was 2-4 hours, the final half-life was 9-11 hours.",[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,2-4,50213,DB01452,Heroin
,1811505,final half-life,"The short half-life of codeine in serum was 2-4 hours, the final half-life was 9-11 hours.",[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,9-11,50214,DB01452,Heroin
,1811505,half-life,In urine we found a short half-life of 1-6 hours as well as a long half-life of 7-12 hours.,[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,1-6,50215,DB01452,Heroin
,1811505,half-life,In urine we found a short half-life of 1-6 hours as well as a long half-life of 7-12 hours.,[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,7-12,50216,DB01452,Heroin
,9742275,plasma concentration ratio,The mean d-methadone:l-methadone plasma concentration ratio was 1.17.,"L-Methadone and D,L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9742275/),,1.17,50693,DB01452,Heroin
,9742275,plasma concentration ratio,"The mean l-methadone:EDDP plasma concentration ratio in the l-methadone group was 22.2 and the d,l-methadone:EDDP plasma concentration ratio was 18.4 .","L-Methadone and D,L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9742275/),,22.2,50694,DB01452,Heroin
,9742275,plasma concentration ratio,"The mean l-methadone:EDDP plasma concentration ratio in the l-methadone group was 22.2 and the d,l-methadone:EDDP plasma concentration ratio was 18.4 .","L-Methadone and D,L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9742275/),,18.4,50695,DB01452,Heroin
,15917146,distribution half-life,"Plasma buprenorphine kinetics was well described by a three-compartment linear model, with a distribution half-life of 7.4+/-2.7 min and an elimination half-life of 463.9+/-152.3 min.",Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917146/),min,7.4,50703,DB01452,Heroin
,15917146,elimination half-life,"Plasma buprenorphine kinetics was well described by a three-compartment linear model, with a distribution half-life of 7.4+/-2.7 min and an elimination half-life of 463.9+/-152.3 min.",Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917146/),min,463.9,50704,DB01452,Heroin
,7894664,recoveries,The recoveries ranged from 92 to 99%.,"Determination of 6-monoacetylmorphine and morphine in plasma, whole blood and urine using high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894664/),%,92 to 99,52603,DB01452,Heroin
,7894664,determination limits,The determination limits were 1 ng/ml for morphine and 4 ng/ml for 6-monoacetylmorphine.,"Determination of 6-monoacetylmorphine and morphine in plasma, whole blood and urine using high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894664/),[ng] / [ml],1,52604,DB01452,Heroin
,7894664,determination limits,The determination limits were 1 ng/ml for morphine and 4 ng/ml for 6-monoacetylmorphine.,"Determination of 6-monoacetylmorphine and morphine in plasma, whole blood and urine using high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894664/),[ng] / [ml],4,52605,DB01452,Heroin
,8926729,Peak heroin concentrations,"Peak heroin concentrations in saliva after smoking heroin base ranged from 3534 (2.6 mg) to 20,580 ng/mL (5.2 mg), and after intravenous administration, concentrations ranged from 6 (10 mg heroin HCl to 30 ng/mL (12 mg heroin HCl.",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],3534,54386,DB01452,Heroin
,8926729,Peak heroin concentrations,"Peak heroin concentrations in saliva after smoking heroin base ranged from 3534 (2.6 mg) to 20,580 ng/mL (5.2 mg), and after intravenous administration, concentrations ranged from 6 (10 mg heroin HCl to 30 ng/mL (12 mg heroin HCl.",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],"20,580",54387,DB01452,Heroin
,8926729,Peak heroin concentrations,"Peak heroin concentrations in saliva after smoking heroin base ranged from 3534 (2.6 mg) to 20,580 ng/mL (5.2 mg), and after intravenous administration, concentrations ranged from 6 (10 mg heroin HCl to 30 ng/mL (12 mg heroin HCl.",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),,6,54388,DB01452,Heroin
,8926729,Peak heroin concentrations,"Peak heroin concentrations in saliva after smoking heroin base ranged from 3534 (2.6 mg) to 20,580 ng/mL (5.2 mg), and after intravenous administration, concentrations ranged from 6 (10 mg heroin HCl to 30 ng/mL (12 mg heroin HCl.",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],30,54389,DB01452,Heroin
,8926729,detection times,Heroin concentrations in saliva after smoking declined slowly; detection times ranged from 4 to 24 h.,Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),h,4 to 24,54390,DB01452,Heroin
,8926729,Peak saliva cocaine concentrations,"Peak saliva cocaine concentrations after intravenous administration ranged from 428 to 1927 ng/mL (N = 7); after smoking, they ranged from 15,852 to 504,880 ng/mL (N = 7).",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],428 to 1927,54391,DB01452,Heroin
,8926729,Peak saliva cocaine concentrations,"Peak saliva cocaine concentrations after intravenous administration ranged from 428 to 1927 ng/mL (N = 7); after smoking, they ranged from 15,852 to 504,880 ng/mL (N = 7).",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],"15,852 to 504,880",54392,DB01452,Heroin
,8926729,Peak plasma cocaine concentrations,"Peak plasma cocaine concentrations after intravenous administration ranged from 122 to 442 ng/mL A = 7), and after smoking, concentrations ranged from 46 to 291 ng/mL A = 7).",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],122 to 442,54393,DB01452,Heroin
,8926729,Peak plasma cocaine concentrations,"Peak plasma cocaine concentrations after intravenous administration ranged from 122 to 442 ng/mL A = 7), and after smoking, concentrations ranged from 46 to 291 ng/mL A = 7).",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],46 to 291,54394,DB01452,Heroin
,8926729,Peak saliva AEME concentrations,Peak saliva AEME concentrations were achieved at 2 min and ranged from 558 to 4374 ng/mL (N = 7).,Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],558 to 4374,54395,DB01452,Heroin
,7039926,systemic bioavailability,"Following oral administration it is rapidly absorbed from the gastrointestinal tract, its systemic bioavailability being dose-dependent and ranging from 70 to 90%.",Clinical pharmacokinetics of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),%,70 to 90,56310,DB01452,Heroin
,7039926,volume of distribution,It distributes rapidly and evenly throughout most tissues and fluids and has a volume of distribution of approximately 0.9L/kg.,Clinical pharmacokinetics of paracetamol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[l] / [kg],0.9,56311,DB01452,Heroin
,7039926,plasma half-life,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),h,1.9 to 2.5,56312,DB01452,Heroin
,7039926,total body clearance,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[ml] / [kg·min],4.5 to 5.5,56313,DB01452,Heroin
,8889672,biovailability,"Buprenorphine biovailability by the sublingual and buccal routes was estimated as 51.4% and 27.8%, respectively, although there was considerable interindividual variability by both routes of administration.","Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889672/),%,51.4,58240,DB01452,Heroin
,8889672,biovailability,"Buprenorphine biovailability by the sublingual and buccal routes was estimated as 51.4% and 27.8%, respectively, although there was considerable interindividual variability by both routes of administration.","Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889672/),%,27.8,58241,DB01452,Heroin
less,8889672,peak plasma concentrations,Norbuprenorphine mean peak plasma concentrations were less than 1 ng/mL and were highly variable among different routes of administration and individuals.,"Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889672/),[ng] / [ml],1,58242,DB01452,Heroin
,29143400,peak concentration (Cmax ),"Mean peak concentration (Cmax ) values for 1 mg (1.51 ng/ml), 2 mg (2.87 ng/ml) and 4 mg (6.02 ng/ml) i.n. exceeded 0.4 mg i.m. (1.27 ng/ml) naloxone.",Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),[ng] / [ml],1.51,63476,DB01452,Heroin
,29143400,peak concentration (Cmax ),"Mean peak concentration (Cmax ) values for 1 mg (1.51 ng/ml), 2 mg (2.87 ng/ml) and 4 mg (6.02 ng/ml) i.n. exceeded 0.4 mg i.m. (1.27 ng/ml) naloxone.",Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),[ng] / [ml],2.87,63477,DB01452,Heroin
,29143400,peak concentration (Cmax ),"Mean peak concentration (Cmax ) values for 1 mg (1.51 ng/ml), 2 mg (2.87 ng/ml) and 4 mg (6.02 ng/ml) i.n. exceeded 0.4 mg i.m. (1.27 ng/ml) naloxone.",Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),[ng] / [ml],6.02,63478,DB01452,Heroin
,29143400,peak concentration (Cmax ),"Mean peak concentration (Cmax ) values for 1 mg (1.51 ng/ml), 2 mg (2.87 ng/ml) and 4 mg (6.02 ng/ml) i.n. exceeded 0.4 mg i.m. (1.27 ng/ml) naloxone.",Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),[ng] / [ml],1.27,63479,DB01452,Heroin
,29143400,Tmax,"All three i.n. doses rapidly achieved plasma levels > 50% of peak concentrations (T50%) by 10 minutes, peaking at 15-30 minutes (Tmax ).",Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),min,15-30,63480,DB01452,Heroin
,29143400,Tmax,"For comparison, the i.m. reference reached Tmax at 10 minutes.",Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),min,10,63481,DB01452,Heroin
,29143400,bioavailability,Mean bioavailability was 47-51% for i.n. relative to i.m. naloxone.,Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),%,47-51,63482,DB01452,Heroin
,17224045,concentration,"Initial plasma R,S-methadone concentration was 1,204 ng/ml.",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),ng,"1,204",65499,DB01452,Heroin
,17224045,maximal observed concentrations,"Decrease in plasma R- and S-methadone concentrations was linear and demonstrated a first-order pharmacokinetics (maximal observed concentrations 566 and 637 ng/ml, half-lives 16.1 and 13.2 hours, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),[ng] / [ml],566,65500,DB01452,Heroin
,17224045,maximal observed concentrations,"Decrease in plasma R- and S-methadone concentrations was linear and demonstrated a first-order pharmacokinetics (maximal observed concentrations 566 and 637 ng/ml, half-lives 16.1 and 13.2 hours, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),[ng] / [ml],637,65501,DB01452,Heroin
,17224045,half-lives,"Decrease in plasma R- and S-methadone concentrations was linear and demonstrated a first-order pharmacokinetics (maximal observed concentrations 566 and 637 ng/ml, half-lives 16.1 and 13.2 hours, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),h,16.1,65502,DB01452,Heroin
,17224045,half-lives,"Decrease in plasma R- and S-methadone concentrations was linear and demonstrated a first-order pharmacokinetics (maximal observed concentrations 566 and 637 ng/ml, half-lives 16.1 and 13.2 hours, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),h,13.2,65503,DB01452,Heroin
,17224045,half-maximum effect [EC50],"TK/TD correlation between naloxone infusion rate and R,S- and R-methadone concentrations fitted well a sigmoidal Emax model (concentration associated with a half-maximum effect [EC50] 334 and 173 ng/ml, Hill coefficient 10.0 and 7.8, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),[ng] / [ml],334,65504,DB01452,Heroin
,17224045,half-maximum effect [EC50],"TK/TD correlation between naloxone infusion rate and R,S- and R-methadone concentrations fitted well a sigmoidal Emax model (concentration associated with a half-maximum effect [EC50] 334 and 173 ng/ml, Hill coefficient 10.0 and 7.8, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),[ng] / [ml],173,65505,DB01452,Heroin
,17224045,Hill coefficient,"TK/TD correlation between naloxone infusion rate and R,S- and R-methadone concentrations fitted well a sigmoidal Emax model (concentration associated with a half-maximum effect [EC50] 334 and 173 ng/ml, Hill coefficient 10.0 and 7.8, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),,10.0,65506,DB01452,Heroin
,17224045,Hill coefficient,"TK/TD correlation between naloxone infusion rate and R,S- and R-methadone concentrations fitted well a sigmoidal Emax model (concentration associated with a half-maximum effect [EC50] 334 and 173 ng/ml, Hill coefficient 10.0 and 7.8, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),,7.8,65507,DB01452,Heroin
,2485290,half-life,"Estimated half-life for methadone was 8.1 hours, which is much shorter than the usual methadone half-life (greater than 24 hours).",Altered methadone pharmacokinetics in pregnancy: implications for dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2485290/),h,8.1,75432,DB01452,Heroin
greater,2485290,half-life,"Estimated half-life for methadone was 8.1 hours, which is much shorter than the usual methadone half-life (greater than 24 hours).",Altered methadone pharmacokinetics in pregnancy: implications for dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2485290/),h,24,75433,DB01452,Heroin
,10097360,clearance,"Results of these parameters showed the following: clearance from 13.3 to 16.2 L.h.1, half-life of the distribution phase from 0.6 to 0.9 min, and half-life of the elimination phase from 21 to 26 min.",Morphine perfused rabbits: a tool for experiments in forensic entomotoxicology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10097360/),1·h·l,13.3 to 16.2,79553,DB01452,Heroin
,10097360,half-life of the distribution phase,"Results of these parameters showed the following: clearance from 13.3 to 16.2 L.h.1, half-life of the distribution phase from 0.6 to 0.9 min, and half-life of the elimination phase from 21 to 26 min.",Morphine perfused rabbits: a tool for experiments in forensic entomotoxicology. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10097360/),min,0.6 to 0.9,79554,DB01452,Heroin
,10097360,half-life of the elimination phase,"Results of these parameters showed the following: clearance from 13.3 to 16.2 L.h.1, half-life of the distribution phase from 0.6 to 0.9 min, and half-life of the elimination phase from 21 to 26 min.",Morphine perfused rabbits: a tool for experiments in forensic entomotoxicology. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10097360/),min,21 to 26,79555,DB01452,Heroin
,16433897,Bioavailability (F),Bioavailability (F) of heroin inhalation was estimated as 52% (95% CI 44-61%).,"Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),%,52,85351,DB01452,Heroin
,16433897,Cl/F,"Cl/F was 930 l/hr (95% CI 799-1061 l/hr) after intravenous administration, and 1939 l/hr (95% CI 1661-2217 l/hr) after inhalation.","Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),[l] / [h],930,85352,DB01452,Heroin
,16433897,Cl/F,"Cl/F was 930 l/hr (95% CI 799-1061 l/hr) after intravenous administration, and 1939 l/hr (95% CI 1661-2217 l/hr) after inhalation.","Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),[l] / [h],1939,85353,DB01452,Heroin
,16433897,reaction time,"After heroin administration, the reaction time was significantly prolonged with 28+/-5.3 msec.","Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),ms,28,85354,DB01452,Heroin
,2046334,half-life,"Following heroin administration, 6-AM was excreted rapidly with an average half-life of 0.6 h.",Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2046334/),h,0.6,87051,DB01452,Heroin
,2046334,half-life,The average half-life for free morphine was 3.6 h and for total morphine was 7.9 h.,Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2046334/),h,3.6,87052,DB01452,Heroin
,2046334,half-life,The average half-life for free morphine was 3.6 h and for total morphine was 7.9 h.,Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2046334/),h,7.9,87053,DB01452,Heroin
,7056023,clearance,"Several changes in P and NP kinetics occurred during repeated dosing with P to the normal subjects: P clearance decreased from 994 to 508 ml/min, NP clearance decreased from 454 to 2210 ml/min, P half-life (t 1/2) increased from 3.3 to 11.8 hr, NP t 1/2 increased from 6.1 to 39.2 hr, and area under the concentration time curves for P and NP were doubled.",Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056023/),[ml] / [min],994,90892,DB01452,Heroin
,7056023,clearance,"Several changes in P and NP kinetics occurred during repeated dosing with P to the normal subjects: P clearance decreased from 994 to 508 ml/min, NP clearance decreased from 454 to 2210 ml/min, P half-life (t 1/2) increased from 3.3 to 11.8 hr, NP t 1/2 increased from 6.1 to 39.2 hr, and area under the concentration time curves for P and NP were doubled.",Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056023/),[ml] / [min],454 to 2210,90893,DB01452,Heroin
,7056023,half-life (t 1/2),"Several changes in P and NP kinetics occurred during repeated dosing with P to the normal subjects: P clearance decreased from 994 to 508 ml/min, NP clearance decreased from 454 to 2210 ml/min, P half-life (t 1/2) increased from 3.3 to 11.8 hr, NP t 1/2 increased from 6.1 to 39.2 hr, and area under the concentration time curves for P and NP were doubled.",Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056023/),h,3.3 to 11.8,90894,DB01452,Heroin
,7056023,t 1/2,"Several changes in P and NP kinetics occurred during repeated dosing with P to the normal subjects: P clearance decreased from 994 to 508 ml/min, NP clearance decreased from 454 to 2210 ml/min, P half-life (t 1/2) increased from 3.3 to 11.8 hr, NP t 1/2 increased from 6.1 to 39.2 hr, and area under the concentration time curves for P and NP were doubled.",Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056023/),h,6.1 to 39.2,90895,DB01452,Heroin
,24887324,peak concentration,"For the 19 subjects who completed the study, morphine concentrations ranged from <300 to 7522 μg/L with a median peak concentration of 5239 μg/L.",Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24887324/),[μg] / [l],5239,103153,DB01452,Heroin
,24887324,peak concentrations,"No specimens were positive for codeine at a cutoff concentration of 2000 μg/L, but 20.2% exceeded 300 μg/L, with peak concentrations of 658 μg/L (284-1540).",Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24887324/),[μg] / [l],658,103154,DB01452,Heroin
,19084595,extended to immediate release bioavailability,The relative extended to immediate release bioavailability was calculated to be 86% by non-compartmental analysis and 93% by deconvolution analysis.,Oral heroin in opioid-dependent patients: pharmacokinetic comparison of immediate and extended release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19084595/),%,86,107149,DB01452,Heroin
,19084595,extended to immediate release bioavailability,The relative extended to immediate release bioavailability was calculated to be 86% by non-compartmental analysis and 93% by deconvolution analysis.,Oral heroin in opioid-dependent patients: pharmacokinetic comparison of immediate and extended release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19084595/),%,93,107150,DB01452,Heroin
,16584286,bioavailability,"The bioavailability of inhaled heroin was estimated to be 53% (95% CI 43.7, 62.3).",Population pharmacokinetics of heroin and its major metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),%,53,116470,DB01452,Heroin
,16584286,terminal half-lives,"The terminal half-lives of heroin and 6-acetylmorphine were estimated to be 7.6 and 21.8 minutes, respectively.",Population pharmacokinetics of heroin and its major metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),min,7.6,116471,DB01452,Heroin
,16584286,terminal half-lives,"The terminal half-lives of heroin and 6-acetylmorphine were estimated to be 7.6 and 21.8 minutes, respectively.",Population pharmacokinetics of heroin and its major metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),min,21.8,116472,DB01452,Heroin
,16584286,clearances,"The clearances of morphine and the morphine-glucuronides were estimated to be 73.6 L/h (95% CI 62.8, 84.4) and between 6 and 10 L/h, respectively.",Population pharmacokinetics of heroin and its major metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),[l] / [h],73.6,116473,DB01452,Heroin
,7967538,apparent plasma terminal half-life,"Both RIAs showed a first-order elimination rate after i.v. intoxication (apparent plasma terminal half-life ranged from 2.9 to 4.7 hours for unchanged morphine and from 3.2 to 4.9 hours for total opiates) and a persistent opiate concentration with rebound after oral ingestion, suggesting a slow release of opiates from the gastrointestinal tract, in dealers and bodypackers.",Morphine disposition in opiate-intoxicated patients: relevance of nonspecific opiate immunoassays. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967538/),h,2.9 to 4.7,118593,DB01452,Heroin
,7967538,apparent plasma terminal half-life,"Both RIAs showed a first-order elimination rate after i.v. intoxication (apparent plasma terminal half-life ranged from 2.9 to 4.7 hours for unchanged morphine and from 3.2 to 4.9 hours for total opiates) and a persistent opiate concentration with rebound after oral ingestion, suggesting a slow release of opiates from the gastrointestinal tract, in dealers and bodypackers.",Morphine disposition in opiate-intoxicated patients: relevance of nonspecific opiate immunoassays. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967538/),h,3.2 to 4.9,118594,DB01452,Heroin
,30849683,LOD,"The LOD were 0.05 ng/mL for U-47700 and N-desmethyl-U-47700 and 0.1 ng/mL for N,N-didesmethyl-U-47700.",Quantification of U-47700 and its metabolites in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30849683/),[ng] / [ml],0.05,121138,DB01452,Heroin
,30849683,LOD,"The LOD were 0.05 ng/mL for U-47700 and N-desmethyl-U-47700 and 0.1 ng/mL for N,N-didesmethyl-U-47700.",Quantification of U-47700 and its metabolites in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30849683/),[ng] / [ml],0.1,121139,DB01452,Heroin
>,30849683,Extraction recovery,Extraction recovery was >79%.,Quantification of U-47700 and its metabolites in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30849683/),%,79,121140,DB01452,Heroin
,9083827,apparent terminal half-lives,The apparent terminal half-lives of morphine-3-glucuronide ranged from 2.2 to 5.2 h for intranasally administered heroin and were 3.0 and 1.7 h for the intramuscularly applied drug.,Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9083827/),h,2.2 to 5.2,125097,DB01452,Heroin
,9083827,apparent terminal half-lives,The apparent terminal half-lives of morphine-3-glucuronide ranged from 2.2 to 5.2 h for intranasally administered heroin and were 3.0 and 1.7 h for the intramuscularly applied drug.,Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9083827/),h,3.0,125098,DB01452,Heroin
,9083827,apparent terminal half-lives,The apparent terminal half-lives of morphine-3-glucuronide ranged from 2.2 to 5.2 h for intranasally administered heroin and were 3.0 and 1.7 h for the intramuscularly applied drug.,Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9083827/),h,1.7,125099,DB01452,Heroin
,9083827,area-under-curve ratio,A mean morphine-3-glucuronide-heroin area-under-curve ratio of 93 for the intranasal route as compared with 38 for the intramuscular route demonstrated that circulating amounts of heroin were about half the size after intranasal administration of the same dose.,Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9083827/),,93,125100,DB01452,Heroin
,9083827,area-under-curve ratio,A mean morphine-3-glucuronide-heroin area-under-curve ratio of 93 for the intranasal route as compared with 38 for the intramuscular route demonstrated that circulating amounts of heroin were about half the size after intranasal administration of the same dose.,Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9083827/),,38,125101,DB01452,Heroin
,25015174,effective concentration at 50 % of maximum (EC50),A saturable maximum effect (E max) model with 0.67 ng/mL effective concentration at 50 % of maximum (EC50) and 91 % E max best described µORO versus buprenorphine plasma concentrations.,"A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015174/),[ng] / [ml],0.67,129419,DB01452,Heroin
,25015174,E max,A saturable maximum effect (E max) model with 0.67 ng/mL effective concentration at 50 % of maximum (EC50) and 91 % E max best described µORO versus buprenorphine plasma concentrations.,"A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015174/),%,91,129420,DB01452,Heroin
,11557911,arterial clearances,"The arterial clearances of diacetylmorphine, monoacetylmorphine, and morphine-d3 were 8.7 +/- 2.6, 6.7 +/- 1.6, and 2.3 +/- 0.3 L/min, respectively.",Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557911/),[l] / [min],8.7,130678,DB01452,Heroin
,11557911,arterial clearances,"The arterial clearances of diacetylmorphine, monoacetylmorphine, and morphine-d3 were 8.7 +/- 2.6, 6.7 +/- 1.6, and 2.3 +/- 0.3 L/min, respectively.",Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557911/),[l] / [min],6.7,130679,DB01452,Heroin
,11557911,arterial clearances,"The arterial clearances of diacetylmorphine, monoacetylmorphine, and morphine-d3 were 8.7 +/- 2.6, 6.7 +/- 1.6, and 2.3 +/- 0.3 L/min, respectively.",Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557911/),[l] / [min],2.3,130680,DB01452,Heroin
,11557911,arterial half-lives,"The arterial half-lives of diacetylmorphine and morphine-d3 were 2. 4 +/- 0.8 and 88 +/- 21 minutes, respectively.",Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557911/),min,2. 4,130681,DB01452,Heroin
,11557911,arterial half-lives,"The arterial half-lives of diacetylmorphine and morphine-d3 were 2. 4 +/- 0.8 and 88 +/- 21 minutes, respectively.",Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557911/),min,88,130682,DB01452,Heroin
,11073290,t 1/2 beta,With a t 1/2 beta of 1.3 - 2.2 min it was rapidly desacetylated to 6-acetylmorphine which was further metabolized to morphine and its 3- and 6-O-glucuronide.,"Pharmacodynamics and pharmacokinetics of intravenously, orally and rectally administered diacetylmorphine in opioid dependents, a two-patient pilot study within a heroin-assisted treatment program. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073290/),min,1.3 - 2.2,131375,DB01452,Heroin
,1357144,initial half-lives,"Diamorphine was rapidly and quantitatively degraded to 6-monoacetylmorphine with initial half-lives of 354, 18 and 3 min at temperatures of 4, 25 and 37 degrees C, respectively.",The effect of temperature and pH on the deacetylation of diamorphine in aqueous solution and in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357144/),min,354,133623,DB01452,Heroin
,1357144,initial half-lives,"Diamorphine was rapidly and quantitatively degraded to 6-monoacetylmorphine with initial half-lives of 354, 18 and 3 min at temperatures of 4, 25 and 37 degrees C, respectively.",The effect of temperature and pH on the deacetylation of diamorphine in aqueous solution and in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357144/),min,18,133624,DB01452,Heroin
,1357144,initial half-lives,"Diamorphine was rapidly and quantitatively degraded to 6-monoacetylmorphine with initial half-lives of 354, 18 and 3 min at temperatures of 4, 25 and 37 degrees C, respectively.",The effect of temperature and pH on the deacetylation of diamorphine in aqueous solution and in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357144/),min,3,133625,DB01452,Heroin
greater,1357144,half-life,At pH 4.0 and 5.6 diamorphine had a half-life of greater than 14 days at all temperatures but at alkaline pH diamorphine was rapidly deacetylated.,The effect of temperature and pH on the deacetylation of diamorphine in aqueous solution and in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357144/),d,14,133626,DB01452,Heroin
,9584342,elimination half-life,"Pharmacokinetic data sets for dextromoramide in each subject were conducted and analysed further, indicating short elimination half-life values (71 min, range 31-152 min).",Determination and pharmacokinetics of dextromoramide in methadone maintenance therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584342/),min,71,135834,DB01452,Heroin
,32375158,half-life,"MCAM plasma concentrations peaked 15-45 min after injection, with a half-life ranging from 13.7 to 199.8 min, and decreased markedly 1 day after injection.","Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32375158/),min,13.7 to 199.8,138215,DB01452,Heroin
,3755014,peak concentration,"Significant drug concentrations appeared in plasma after intrathecal heroin (peak concentration 47.8 +/- 9.0 nmol/L, time to peak concentration 10 +/- 2.4 min); after intrathecal morphine plasma drug concentrations were significantly lower (8.1 +/- 1.0 nmol/L; P less than 0.002) and significantly later (216 +/- 39 min; P less than 0.002).",Intrathecal morphine and heroin in humans: six-hour drug levels in spinal fluid and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755014/),[nM] / [l],47.8,149516,DB01452,Heroin
,3755014,time to peak concentration,"Significant drug concentrations appeared in plasma after intrathecal heroin (peak concentration 47.8 +/- 9.0 nmol/L, time to peak concentration 10 +/- 2.4 min); after intrathecal morphine plasma drug concentrations were significantly lower (8.1 +/- 1.0 nmol/L; P less than 0.002) and significantly later (216 +/- 39 min; P less than 0.002).",Intrathecal morphine and heroin in humans: six-hour drug levels in spinal fluid and plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755014/),min,10,149517,DB01452,Heroin
,3755014,Elimination half-life,Elimination half-life of heroin from spinal fluid (43 +/- 5 min) was significantly shorter than for morphine (73 +/- 5 min; P less than 0.02).,Intrathecal morphine and heroin in humans: six-hour drug levels in spinal fluid and plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755014/),min,43,149518,DB01452,Heroin
,3755014,Elimination half-life,Elimination half-life of heroin from spinal fluid (43 +/- 5 min) was significantly shorter than for morphine (73 +/- 5 min; P less than 0.02).,Intrathecal morphine and heroin in humans: six-hour drug levels in spinal fluid and plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755014/),min,73,149519,DB01452,Heroin
,550136,apparent excretory half-life,The apparent excretory half-life of methadone in the neonate was 32.5 hr.,Methadone disposition during the perinatal period in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/550136/),h,32.5,150698,DB01452,Heroin
,17099560,bioavailability,Its mean bioavailability is around 75%.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,75,153478,DB01452,Heroin
,17099560,volume of distribution,Its volume of distribution is of around 4 L/kg.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[l] / [kg],4,153479,DB01452,Heroin
,17099560,half-life elimination,The value of half-life elimination is of around 22 hours.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),h,22,153480,DB01452,Heroin
,17099560,bioavibility,"Thus, bioavibility ranges from 36 to 100%.",[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,36 to 100,153481,DB01452,Heroin
,17099560,plasmatic target,The methadone plasmatic target value of 400 microg/ml can be recommended for therapeutic drug monitoring.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[μg] / [ml],400,153482,DB01452,Heroin
,7420276,Metabolic clearance,Metabolic clearance of 2916 +/- 321 ml/min are largely extrahepatic and are sixfold greater than hepatic blood flow.,Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420276/),[ml] / [min],2916,157034,DB01452,Heroin
,7420276,terminal half-life,"Nevertheless, the terminal half-life of 60-90 min resembles that of morphine and is maintained by the rate-determining return of distributed heroin from esterase-free tissues.",Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420276/),min,60-90,157035,DB01452,Heroin
,7420276,renal clearances,Normal renal clearances of 43 +/- 6 ml/min result in 1.6 +/- 0.2% of the dose being renally excreted unchanged.,Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420276/),[ml] / [min],43,157036,DB01452,Heroin
,7420276,overall volume of distribution,"The large overall volume of distribution, 344 +/- 60 liters, is indicative of heroin's wide distribution and lipophilicity, which rapidly equilibrates heroin in the plasma with the cerebrospinal fluid.",Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420276/),l,344,157037,DB01452,Heroin
,7420276,total clearance,"Its time course is close to that of heroin, although the total clearance (2200 ml/min) and overall volumes of distribution (90-170 liters) were less.",Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420276/),[ml] / [min],2200,157038,DB01452,Heroin
,7420276,overall volumes of distribution,"Its time course is close to that of heroin, although the total clearance (2200 ml/min) and overall volumes of distribution (90-170 liters) were less.",Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420276/),l,90-170,157039,DB01452,Heroin
better,9234868,recovery,After addition of ethylmorphine as internal standard the plasma samples were extracted using C18 ODS-2 solid-phase columns with a recovery better than 80%.,High-performance liquid chromatographic monitoring of intravenously administered diacetylmorphine and morphine and their metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234868/),%,80,158273,DB01452,Heroin
,8799518,steady-state plasma concentration,"2. Following both the 50 micrograms kg-1 or 200 micrograms kg-1 loading doses the mean steady-state plasma concentration (+/- s.d.) of morphine, M3G and M6G were 86 +/- 52 ng ml-1, 703 +/- 400 ng ml-1 and 48 +/- 28 ng ml-1 respectively and morphine clearance was found to be 4.6 +/- 3.2 ml min-1 kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ng] / [ml],86,183779,DB01452,Heroin
,8799518,steady-state plasma concentration,"2. Following both the 50 micrograms kg-1 or 200 micrograms kg-1 loading doses the mean steady-state plasma concentration (+/- s.d.) of morphine, M3G and M6G were 86 +/- 52 ng ml-1, 703 +/- 400 ng ml-1 and 48 +/- 28 ng ml-1 respectively and morphine clearance was found to be 4.6 +/- 3.2 ml min-1 kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ng] / [ml],703,183780,DB01452,Heroin
,8799518,steady-state plasma concentration,"2. Following both the 50 micrograms kg-1 or 200 micrograms kg-1 loading doses the mean steady-state plasma concentration (+/- s.d.) of morphine, M3G and M6G were 86 +/- 52 ng ml-1, 703 +/- 400 ng ml-1 and 48 +/- 28 ng ml-1 respectively and morphine clearance was found to be 4.6 +/- 3.2 ml min-1 kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ng] / [ml],48,183781,DB01452,Heroin
,8799518,clearance,"2. Following both the 50 micrograms kg-1 or 200 micrograms kg-1 loading doses the mean steady-state plasma concentration (+/- s.d.) of morphine, M3G and M6G were 86 +/- 52 ng ml-1, 703 +/- 400 ng ml-1 and 48 +/- 28 ng ml-1 respectively and morphine clearance was found to be 4.6 +/- 3.2 ml min-1 kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ml] / [kg·min],4.6,183782,DB01452,Heroin
,8799518,formation clearance,"3. M3G formation clearance was estimated to be 2.5 +/- 1.8 ml min-1 kg-1, and the formation clearance of M6G was estimated to be 0.46 +/- 0.32 ml min-1 kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ml] / [kg·min],2.5,183783,DB01452,Heroin
,8799518,formation clearance,"3. M3G formation clearance was estimated to be 2.5 +/- 1.8 ml min-1 kg-1, and the formation clearance of M6G was estimated to be 0.46 +/- 0.32 ml min-1 kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ml] / [kg·min],0.46,183784,DB01452,Heroin
,8799518,clearance,"4. M3G metabolite clearance was 0.46 +/- 0.60 ml min-1 kg-1, the elimination half-life was 11.1 +/- 11.3 h and the volume of distribution was 0.55 +/- 1.13 l kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ml] / [kg·min],0.46,183785,DB01452,Heroin
,8799518,elimination half-life,"4. M3G metabolite clearance was 0.46 +/- 0.60 ml min-1 kg-1, the elimination half-life was 11.1 +/- 11.3 h and the volume of distribution was 0.55 +/- 1.13 l kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),h,11.1,183786,DB01452,Heroin
,8799518,volume of distribution,"4. M3G metabolite clearance was 0.46 +/- 0.60 ml min-1 kg-1, the elimination half-life was 11.1 +/- 11.3 h and the volume of distribution was 0.55 +/- 1.13 l kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[l] / [kg],0.55,183787,DB01452,Heroin
,8799518,clearance,"M6G metabolite clearance was 0.71 +/- 0.36 ml min-1 kg-1, the elimination half-life was 18.2 +/- 13.6 h and the volume of distribution was 1.03 +/- 0.88 l kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ml] / [kg·min],0.71,183788,DB01452,Heroin
,8799518,elimination half-life,"M6G metabolite clearance was 0.71 +/- 0.36 ml min-1 kg-1, the elimination half-life was 18.2 +/- 13.6 h and the volume of distribution was 1.03 +/- 0.88 l kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),h,18.2,183789,DB01452,Heroin
,8799518,volume of distribution,"M6G metabolite clearance was 0.71 +/- 0.36 ml min-1 kg-1, the elimination half-life was 18.2 +/- 13.6 h and the volume of distribution was 1.03 +/- 0.88 l kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[l] / [kg],1.03,183790,DB01452,Heroin
,8799518,steady-state plasma concentration ratios,"7. M3G: morphine and M6G: morphine steady-state plasma concentration ratios were 11.0 +/- 10.8 and 0.8 +/- 0.8, respectively.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),,11.0,183791,DB01452,Heroin
,8799518,steady-state plasma concentration ratios,"7. M3G: morphine and M6G: morphine steady-state plasma concentration ratios were 11.0 +/- 10.8 and 0.8 +/- 0.8, respectively.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),,0.8,183792,DB01452,Heroin
below,18334103,Mor/Cod,The Mor/Cod in plasma were below 1 for both UMs and EMs during the first 12 h.,CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18334103/),,1,189803,DB01452,Heroin
>,18334103,ratios,"After 12 h, 9% of the 11 UM and none of the 12 EM had ratios > 1.",CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18334103/),,1,189804,DB01452,Heroin
below,18334103,Mor/Cod ratios,"In urine, Mor/Cod ratios were below one for all EMs and UMs during the first 12 h.",CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18334103/),,one,189805,DB01452,Heroin
>,18334103,Mor/Cod ratios,"Thus, CYP2D6 genotyping in general will not explain Mor/Cod ratios > 1 in plasma or urine, unless the time of drug intake is more than 24 h previous.",CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18334103/),,1,189806,DB01452,Heroin
,32533977,Ki,"Using radioligand binding assays, U-47700 displayed high affinity for μ-opioid receptors (Ki = 11.1 nM) whereas metabolites were more than 18-fold weaker.","Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533977/),nM,11.1,196033,DB01452,Heroin
,11599592,Excretion half-life,Excretion half-life mean +/- SD for Tmor was 3.11 +/- 0.30 h.,"Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),h,3.11,212732,DB01452,Heroin
,11599592,peak urine concentrations,"Range (median) of peak urine concentrations, time to peak, time to last positive sample for low cutoff (300 ng/mL) and high cutoff (2000 ng/mL) for Tmor following lower doses (< or = 7 mg) were, respectively, 1392-9250 (3620) ng/mL, 1.2-6.2 (2.3) h, 7.4-31.9 (7.4) h, and 0-10.1 (4.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),[ng] / [ml],1392-9250,212733,DB01452,Heroin
,11599592,time to peak,"Range (median) of peak urine concentrations, time to peak, time to last positive sample for low cutoff (300 ng/mL) and high cutoff (2000 ng/mL) for Tmor following lower doses (< or = 7 mg) were, respectively, 1392-9250 (3620) ng/mL, 1.2-6.2 (2.3) h, 7.4-31.9 (7.4) h, and 0-10.1 (4.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),h,1.2-6.2,212734,DB01452,Heroin
,11599592,time to peak,"Range (median) of peak urine concentrations, time to peak, time to last positive sample for low cutoff (300 ng/mL) and high cutoff (2000 ng/mL) for Tmor following lower doses (< or = 7 mg) were, respectively, 1392-9250 (3620) ng/mL, 1.2-6.2 (2.3) h, 7.4-31.9 (7.4) h, and 0-10.1 (4.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),h,7.4-31.9,212735,DB01452,Heroin
,11599592,time to last positive sample,"Range (median) of peak urine concentrations, time to peak, time to last positive sample for low cutoff (300 ng/mL) and high cutoff (2000 ng/mL) for Tmor following lower doses (< or = 7 mg) were, respectively, 1392-9250 (3620) ng/mL, 1.2-6.2 (2.3) h, 7.4-31.9 (7.4) h, and 0-10.1 (4.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),h,7.4-31.9,212736,DB01452,Heroin
,11599592,time to last positive sample,"Range (median) of peak urine concentrations, time to peak, time to last positive sample for low cutoff (300 ng/mL) and high cutoff (2000 ng/mL) for Tmor following lower doses (< or = 7 mg) were, respectively, 1392-9250 (3620) ng/mL, 1.2-6.2 (2.3) h, 7.4-31.9 (7.4) h, and 0-10.1 (4.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),h,0-10.1,212737,DB01452,Heroin
,11599592,peak Fmor concentrations,"Range (median) of peak Fmor concentrations and time to last positive using a cutoff of 100 ng/mL for low and high doses were, respectively, 117-1160 (415) ng/mL, 1.2-10.1 (4.5) h and 150-2580 (1400) ng/mL, 2.3-29.1 (9.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),[ng] / [ml],117-1160,212738,DB01452,Heroin
,11599592,time to last positive,"Range (median) of peak Fmor concentrations and time to last positive using a cutoff of 100 ng/mL for low and high doses were, respectively, 117-1160 (415) ng/mL, 1.2-10.1 (4.5) h and 150-2580 (1400) ng/mL, 2.3-29.1 (9.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),h,1.2-10.1,212739,DB01452,Heroin
,11599592,peak urine concentrations,The range (median) of peak urine concentrations for 6-AM was 6.1-568 (124) ng/mL.,"Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),[ng] / [ml],6.1-568,212740,DB01452,Heroin
,11599592,percent of heroin excreted into urine as,The range (median) values for percent of heroin excreted into urine as Tmor was 12.8-88.5% (51.0).,"Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),%,12.8-88.5,212741,DB01452,Heroin
,11599592,Tmor,The range (median) values for percent of heroin excreted into urine as Tmor was 12.8-88.5% (51.0).,"Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),%,12.8-88.5,212742,DB01452,Heroin
,2839637,half-time of blockade,"The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr).",Duration of occupancy of opiate receptors by naltrexone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2839637/),h,72 to 108,214228,DB01452,Heroin
,2839637,half-time of blockade,"The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr).",Duration of occupancy of opiate receptors by naltrexone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2839637/),h,4-12,214229,DB01452,Heroin
,2839637,half-time of the terminal phase,"The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr).",Duration of occupancy of opiate receptors by naltrexone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2839637/),h,96,214230,DB01452,Heroin
,11177493,elimination half-life,"Auto-induction of methadone metabolism was demonstrated and it was observed that clearance of methadone was significantly lower (p < 0.05) in opiate addicts at the start of treatment (median elimination half-life, 128-hours) than in those who had reached steady-state (median elimination half-life, 48 hours).",Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11177493/),h,128,215454,DB01452,Heroin
,11177493,elimination half-life,"Auto-induction of methadone metabolism was demonstrated and it was observed that clearance of methadone was significantly lower (p < 0.05) in opiate addicts at the start of treatment (median elimination half-life, 128-hours) than in those who had reached steady-state (median elimination half-life, 48 hours).",Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11177493/),h,48,215455,DB01452,Heroin
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,95.9,220664,DB01452,Heroin
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,98,220665,DB01452,Heroin
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,94.8,220666,DB01452,Heroin
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,102.4,220667,DB01452,Heroin
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,1.8,220668,DB01452,Heroin
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,2.7,220669,DB01452,Heroin
,26339186,absolute recoveries,"The absolute recoveries of MDN and EDDP were 95.9%-98.9% and 94.8%-102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),%,3.9,220670,DB01452,Heroin
,26339186,limits of detection,"The limits of detection of MDN and EDDP were 4 and 5 ng/mL, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),[ng] / [ml],4,220671,DB01452,Heroin
,26339186,limits of detection,"The limits of detection of MDN and EDDP were 4 and 5 ng/mL, respectively.",Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26339186/),[ng] / [ml],5,220672,DB01452,Heroin
,20465864,Recoveries,Recoveries of analytes of interest were between 81 and 109%.,Method for the quantification of diamorphine and its metabolites in pediatric plasma samples by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465864/),%,81 and 109,223783,DB01452,Heroin
,20465864,Limits of detection,"Limits of detection and quantitation were 0.08-0.37 ng/mL and 0.28-1.22 ng/mL, respectively.",Method for the quantification of diamorphine and its metabolites in pediatric plasma samples by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465864/),[ng] / [ml],0.08-0.37,223784,DB01452,Heroin
,20465864,Limits of detection,"Limits of detection and quantitation were 0.08-0.37 ng/mL and 0.28-1.22 ng/mL, respectively.",Method for the quantification of diamorphine and its metabolites in pediatric plasma samples by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465864/),[ng] / [ml],0.28-1.22,223785,DB01452,Heroin
,20465864,q,"Limits of detection and quantitation were 0.08-0.37 ng/mL and 0.28-1.22 ng/mL, respectively.",Method for the quantification of diamorphine and its metabolites in pediatric plasma samples by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465864/),[ng] / [ml],0.08-0.37,223786,DB01452,Heroin
,20465864,q,"Limits of detection and quantitation were 0.08-0.37 ng/mL and 0.28-1.22 ng/mL, respectively.",Method for the quantification of diamorphine and its metabolites in pediatric plasma samples by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465864/),[ng] / [ml],0.28-1.22,223787,DB01452,Heroin
,905632,first pass effect,The values for the first pass effect were 79.6 +/- 4.6% and 78.0 +/- 3.0% for acute and chronic treatment respectively.,Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/905632/),%,79.6,225306,DB01452,Heroin
,905632,first pass effect,The values for the first pass effect were 79.6 +/- 4.6% and 78.0 +/- 3.0% for acute and chronic treatment respectively.,Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/905632/),%,78.0,225307,DB01452,Heroin
,905632,apparent chronic release rate (ACRR),From our pharmacokinetic data an apparent chronic release rate (ACRR) for a sustained release preparation of naltrexone was calculated as 11.8 microgram/kg/hr.,Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/905632/),[μg] / [h·kg],11.8,225308,DB01452,Heroin
,758459,t1/2,The inhibition of the spontaneous hydrolysis of heroin in fresh dog plasma on blood (t1/2 = 8 min) is effected by 10 mg of sodium fluoride/ml (t1/2 = 40 min) and 35 microgram of tetraethyl pyrophosphate/ml (t1/2 = 415 min).,Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),min,8,226476,DB01452,Heroin
,758459,t1/2,The inhibition of the spontaneous hydrolysis of heroin in fresh dog plasma on blood (t1/2 = 8 min) is effected by 10 mg of sodium fluoride/ml (t1/2 = 40 min) and 35 microgram of tetraethyl pyrophosphate/ml (t1/2 = 415 min).,Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),min,40,226477,DB01452,Heroin
,758459,t1/2,The inhibition of the spontaneous hydrolysis of heroin in fresh dog plasma on blood (t1/2 = 8 min) is effected by 10 mg of sodium fluoride/ml (t1/2 = 40 min) and 35 microgram of tetraethyl pyrophosphate/ml (t1/2 = 415 min).,Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),min,415,226478,DB01452,Heroin
,758459,extraction efficiencies,Modified extraction procedures developed for enzyme-inhibited plasma at pH 4.5 have high extraction efficiencies (86--100%) and permit isolation of undergraded heroin from its metabolites.,Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),%,86--100,226479,DB01452,Heroin
,758459,Efficiencies,Efficiencies of these TLC recoveries were 81 +/- 1% for heroin and 82 +/- 1% for morphine.,Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),%,81,226480,DB01452,Heroin
,758459,Efficiencies,Efficiencies of these TLC recoveries were 81 +/- 1% for heroin and 82 +/- 1% for morphine.,Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),%,82,226481,DB01452,Heroin
,758459,apparent partition coefficient,"The apparent partition coefficient is 1.4 +/- 0.2 between red blood cells and plasma water, and it is 0.8 +/- 0.1 between red blood cells and dog plasma.",Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),,1.4,226482,DB01452,Heroin
,758459,apparent partition coefficient,"The apparent partition coefficient is 1.4 +/- 0.2 between red blood cells and plasma water, and it is 0.8 +/- 0.1 between red blood cells and dog plasma.",Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),,0.8,226483,DB01452,Heroin
,9354306,oral clearance,The population mean oral clearance of methadone was 6.9+/-1.5 s.d. l h(-1) (5.3+/-1.2 s.d.,The pharmacokinetics of methadone in healthy subjects and opiate users. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),[l] / [h],6.9,233908,DB01452,Heroin
,9354306,oral clearance,The population mean oral clearance of methadone was 6.9+/-1.5 s.d. l h(-1) (5.3+/-1.2 s.d.,The pharmacokinetics of methadone in healthy subjects and opiate users. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),,5.3,233909,DB01452,Heroin
,9354306,clearance,"The former indicated a significantly lower clearance for opiate users (3.2+/-0.3 s.d. l h(-1), P<0.001); 95% CI for the difference = -3 to -6 l h(-1) and no difference in the population mean values of V/F (212+/-27 s.d. l and 239+/-121 s.d. l, P=0.15), while according to the latter analysis addiction was a covariate for V/F but not for oral clearance.",The pharmacokinetics of methadone in healthy subjects and opiate users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),,3.2,233910,DB01452,Heroin
,9354306,V/F,"The former indicated a significantly lower clearance for opiate users (3.2+/-0.3 s.d. l h(-1), P<0.001); 95% CI for the difference = -3 to -6 l h(-1) and no difference in the population mean values of V/F (212+/-27 s.d. l and 239+/-121 s.d. l, P=0.15), while according to the latter analysis addiction was a covariate for V/F but not for oral clearance.",The pharmacokinetics of methadone in healthy subjects and opiate users. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),d·l·s,212,233911,DB01452,Heroin
,9354306,V/F,"The former indicated a significantly lower clearance for opiate users (3.2+/-0.3 s.d. l h(-1), P<0.001); 95% CI for the difference = -3 to -6 l h(-1) and no difference in the population mean values of V/F (212+/-27 s.d. l and 239+/-121 s.d. l, P=0.15), while according to the latter analysis addiction was a covariate for V/F but not for oral clearance.",The pharmacokinetics of methadone in healthy subjects and opiate users. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),d·l·s,239,233912,DB01452,Heroin
,9354306,elimination half-life,The median elimination half-life of methadone in healthy subjects was 33-46 h depending on the method used to calculate this parameter.,The pharmacokinetics of methadone in healthy subjects and opiate users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),h,33-46,233913,DB01452,Heroin
,9354306,long terminal elimination half-life,"Estimates of the long terminal elimination half-life of methadone (33-46 h in healthy subjects and, possibly, longer in opiate users) indicated that accurate measurement of this parameter requires a duration of sampling longer than that used in this study.",The pharmacokinetics of methadone in healthy subjects and opiate users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354306/),h,33-46,233914,DB01452,Heroin
,14534521,bioavailability,"Intramuscularly administered diacetylmorphine (</=200-250 mg) exhibited linear diacetylmorphine, monoacetylmorphine, and morphine kinetics and resulted in sustained diacetylmorphine exposures (bioavailability, 380% +/- 157% [mean +/- SD]) and in lower and delayed peak monoacetylmorphine and morphine concentrations as compared with intravenous administration.",Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534521/),%,380,240255,DB01452,Heroin
,14534521,bioavailabilities,"Oral diacetylmorphine (</=600 mg) yielded negligible systemic diacetylmorphine and monoacetylmorphine exposures but was associated with linear kinetics and high bioavailabilities for morphine (67% +/- 19%), morphine-3-glucuronide (205% +/- 52%), and morphine-6-glucuronide (180% +/- 61%).",Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534521/),%,67,240256,DB01452,Heroin
,14534521,bioavailabilities,"Oral diacetylmorphine (</=600 mg) yielded negligible systemic diacetylmorphine and monoacetylmorphine exposures but was associated with linear kinetics and high bioavailabilities for morphine (67% +/- 19%), morphine-3-glucuronide (205% +/- 52%), and morphine-6-glucuronide (180% +/- 61%).",Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534521/),%,205,240257,DB01452,Heroin
,14534521,bioavailabilities,"Oral diacetylmorphine (</=600 mg) yielded negligible systemic diacetylmorphine and monoacetylmorphine exposures but was associated with linear kinetics and high bioavailabilities for morphine (67% +/- 19%), morphine-3-glucuronide (205% +/- 52%), and morphine-6-glucuronide (180% +/- 61%).",Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534521/),%,180,240258,DB01452,Heroin
,12501913,plasma elimination half-life,"In opiate-naïve subjects, intravenous (i.v.) ACOD showed a plasma elimination half-life of 237 +/- 18 min, urine peak concentrations 2 h after administration, and a detection window of 8 h.",Acetylcodeine as a urinary marker to differentiate the use of street heroin and pharmaceutical heroin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501913/),min,237,260935,DB01452,Heroin
,1888639,steady-state plasma morphine concentration,2. The mean steady-state plasma morphine concentration (+/- s.d.) for a diamorphine infusion rate of 15 micrograms kg-1 h-1 was 62.5 +/- 22.8 ng ml-1.,Morphine kinetics after diamorphine infusion in premature neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888639/),[ng] / [ml],62.5,263250,DB01452,Heroin
,1888639,clearance,"3. Morphine clearance was 3.6 +/- 0.9 ml min-1 kg-1, the elimination half-life was 8.9 +/- 3.3 h and the volume of distribution was 2.7 +/- 1.01 kg-1.",Morphine kinetics after diamorphine infusion in premature neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888639/),[ml] / [kg·min],3.6,263251,DB01452,Heroin
,1888639,elimination half-life,"3. Morphine clearance was 3.6 +/- 0.9 ml min-1 kg-1, the elimination half-life was 8.9 +/- 3.3 h and the volume of distribution was 2.7 +/- 1.01 kg-1.",Morphine kinetics after diamorphine infusion in premature neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888639/),h,8.9,263252,DB01452,Heroin
,1888639,volume of distribution,"3. Morphine clearance was 3.6 +/- 0.9 ml min-1 kg-1, the elimination half-life was 8.9 +/- 3.3 h and the volume of distribution was 2.7 +/- 1.01 kg-1.",Morphine kinetics after diamorphine infusion in premature neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888639/),1/[kg],2.7,263253,DB01452,Heroin
,21862022,LODs,"The LODs were 200 pg/mL for MET and EMDP, and 400 pg/mL for EDDP.",Cation-selective exhaustive injection and sweeping micellar electrokinetic chromatography for the analysis of methadone and its metabolites in serum of heroin addicts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21862022/),[pg] / [ml],200,267439,DB01452,Heroin
,21862022,LODs,"The LODs were 200 pg/mL for MET and EMDP, and 400 pg/mL for EDDP.",Cation-selective exhaustive injection and sweeping micellar electrokinetic chromatography for the analysis of methadone and its metabolites in serum of heroin addicts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21862022/),[pg] / [ml],400,267440,DB01452,Heroin
,28430384,Bioavailability,(1) Bioavailability was F% = 25-28% for intranasal naloxone.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),%,25-28,271021,DB01452,Heroin
,28430384,bioavailability (F%,Sublingual had low bioavailability (F% = 2%) and was not considered further.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),%,2,271022,DB01452,Heroin
,28430384,Cmax,Mean Cmax values for 8 mg (12.83 ng/ml) and 16 mg (18.25 ng/ml) intranasal exceeded 1 mg intravenous (9.64 ng/ml) naloxone.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),[ng] / [ml],12.83,271023,DB01452,Heroin
,28430384,Cmax,Mean Cmax values for 8 mg (12.83 ng/ml) and 16 mg (18.25 ng/ml) intranasal exceeded 1 mg intravenous (9.64 ng/ml) naloxone.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),[ng] / [ml],18.25,271024,DB01452,Heroin
,28430384,Cmax,Mean Cmax values for 8 mg (12.83 ng/ml) and 16 mg (18.25 ng/ml) intranasal exceeded 1 mg intravenous (9.64 ng/ml) naloxone.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),[ng] / [ml],9.64,271025,DB01452,Heroin
,28430384,t50%,"(2) Following intranasal administration, t50% was reached within 8 minutes and tmax within 20 minutes.",Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),min,8,271026,DB01452,Heroin
,28430384,tmax,"(2) Following intranasal administration, t50% was reached within 8 minutes and tmax within 20 minutes.",Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),min,20,271027,DB01452,Heroin
,28430384,absorption from dosing to 30 minutes (AUC30 ),Mean naloxone absorption from dosing to 30 minutes (AUC30 ) was greater following 8 mg (4.17 h × ng/ml) and 16 mg (5.91 h × ng/ml) intranasal than following 1 mg intravenous (1.70 h × ng/ml) administration.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),[h·ng] / [ml],4.17,271028,DB01452,Heroin
,28430384,absorption from dosing to 30 minutes (AUC30 ),Mean naloxone absorption from dosing to 30 minutes (AUC30 ) was greater following 8 mg (4.17 h × ng/ml) and 16 mg (5.91 h × ng/ml) intranasal than following 1 mg intravenous (1.70 h × ng/ml) administration.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),[h·ng] / [ml],5.91,271029,DB01452,Heroin
,28430384,absorption from dosing to 30 minutes (AUC30 ),Mean naloxone absorption from dosing to 30 minutes (AUC30 ) was greater following 8 mg (4.17 h × ng/ml) and 16 mg (5.91 h × ng/ml) intranasal than following 1 mg intravenous (1.70 h × ng/ml) administration.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),[h·ng] / [ml],1.70,271030,DB01452,Heroin
